Thymalfasin (Thymosin α1)
(Synonyms: 胸腺法新; Thymosin α1) 目录号 : GC30108
An immunomodulator peptide
Cas No.:62304-98-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Thymosin α1 is an immunomodulator peptide formed from the cleavage of prothymosin α.1 Thymosin α1 inhibits the growth of 5TGM1 mouse and OPM-2, LP-1, and U266 human multiple myeloma cells in vitro but not in vivo.2 It also increases CD3- and CD28-induced T cell proliferation in C57BL/KaLwRij splenocytes but not in allogeneic mixed lymphocyte reactions using C57BL/KaLwRij and BALB/c splenocyte co-cultures when used at a concentration of 20 μM. Thymosin α1 also inhibits the growth and migration of H1299, NL9980, and L9981 non-small cell lung cancer (NSCLC) cells that express high levels of programmed cell death ligand 1 (PD-L1) but not of A549 and SPC-A-1 NSCLC cells that express low PD-L1 levels.3 It also decreases the number of metastatic lesions in a L9981, but not an A549, NSCLC mouse xenograft model when administered at a dose of 20 mg/kg per day. Thymosin α1 (200 μg/kg) increases indoleamine 2,3-dioxygenase 1 (IDO1) expression and IL-10 levels and decreases IL-1β and TNF-α production in the lung in a p.Phe508del mutant cystic fibrosis transmembrane conductance regulator (CFTRF508del/F508del) mouse model of cystic fibrosis and chronic A. fumigatus infection.4
1.Manrow, R.E., Leone, A., Krug, M.S., et al.The human prothymosin α gene family contains several processed pseudogenes lacking deleterious lesionsGenomics13(2)319-331(1992) 2.Binsfeld, M., Hannon, M., Otjacques, E., et al.Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantationCancer Immunol. Immunother.64(8)989-998(2015) 3.Bo, C., Wu, Q., Zhao, H., et al.Thymosin α1 suppresses migration and invasion of PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3-MMP2 signalingOnco. Targets Ther.117255-7270(2018) 4.Romani, L., Oikonomou, V., Moretti, S., et al.Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosisNat. Med.23(5)590-600(2017)
| Cas No. | 62304-98-7 | SDF | |
| 别名 | 胸腺法新; Thymosin α1 | ||
| Canonical SMILES | N-acetyl-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn | ||
| 分子式 | C129H215N33O55 | 分子量 | 3108.28 |
| 溶解度 | Water : 0.3 mg/mL (0.10 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3217 mL | 1.6086 mL | 3.2172 mL |
| 5 mM | 0.0643 mL | 0.3217 mL | 0.6434 mL |
| 10 mM | 0.0322 mL | 0.1609 mL | 0.3217 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B
J Gastroenterol Hepatol 2004 Dec;19(12):S73-5.15641208
Chronic hepatitis B virus (HBV) infection is a serious clinical problem because of its world-wide distribution and potential adverse sequelae. Globally, there are approximately 350 million people infected with chronic HBV, 75% of whom live in the Asia-Pacific region. Interferon-alfa and direct anti-viral agents such as lamivudine and adefovir are effective in the therapy of chronic HBV infection but the efficacy is far from satisfactory, particularly in perinatally infected patients, patients with lower ALT levels and those with HBeAg-negative chronic hepatitis B. Thymalfasin (thymosin-alphal) is an immunoregulatory agent able to enhance Thl response. It has been shown to trigger maturational events in lymphocytes, to augment T-cell function, and to promote reconstitution of immune defects. Studies are underway in both monotherapy and combination therapy with Thymalfasin and interferon and results are promising.
Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B
J Gastroenterol Hepatol 2004 Dec;19 Suppl 6:S73-5.15546254 10.1111/j.1440-1746.2004.03633.x
Chronic hepatitis B virus (HBV) infection is a serious clinical problem because of its worldwide distribution and potential adverse sequelae. Globally, there are approximately 350 million people infected with chronic HBV, 75% of whom live in the Asia-Pacific region. Interferon-alfa and direct antiviral agents such as lamivudine and adefovir are effective in the therapy of chronic HBV infection but the efficacy is far from satisfactory, particularly in perinatally infected patients, patients with lower ALT levels and those with HBeAg-negative chronic hepatitis B. Thymalfasin (thymosin-alpha1) is an immunoregulatory agent able to enhance Th1 response. It has been shown to trigger maturational events in lymphocytes, to augment T-cell function, and to promote reconstitution of immune defects. Studies are underway in both monotherapy and combination therapy with Thymalfasin and interferon and results are promising.
Thymalfasin: an immune system enhancer for the treatment of liver disease
J Gastroenterol Hepatol 2004 Dec;19(12):S69-72.15641207
Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases, including chronic hepatitis B and C, AIDS, primary immunodeficiency diseases, depressed response to vaccination and cancer. The basis for effectiveness in these conditions is primarily through modulation of immunological responsiveness, as Thymalfasin has been shown to have beneficial effects on numerous immune system parameters and to increase T-cell differentiation and maturation. Thymalfasin is responsible for reconstitution of immune function when thymic tissue is given back to thymectomized animals. In addition, Thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where Thymalfasin has shown antitumor effects.
Thymalfasin: an immune system enhancer for the treatment of liver disease
J Gastroenterol Hepatol 2004 Dec;19 Suppl 6:S69-72.15546253 10.1111/j.1440-1746.2004.03635.x
Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Th1 immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases, including chronic hepatitis B and C, AIDS, primary immunodeficiency diseases, depressed response to vaccination and cancer. The basis for effectiveness in these conditions is primarily through modulation of immunological responsiveness, as Thymalfasin has been shown to have beneficial effects on numerous immune system parameters and to increase T-cell differentiation and maturation. Thymalfasin is responsible for reconstitution of immune function when thymic tissue is given back to thymectomized animals. In addition, Thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where Thymalfasin has shown antitumor effects.
Thymalfasin for the treatment of chronic hepatitis C infection
Expert Rev Anti Infect Ther 2005 Dec;3(6):885-92.16307501 10.1586/14787210.3.6.885
Approximately 50% of treatment-naive hepatitis C patients fail to achieve a sustained virologic response with standard peginterferon and ribavirin therapy. Patients who are infected with genotype 1 have high viral loads and are nonresponders to previous therapy, and are even more difficult to treat, underscoring the need for new therapeutic options. Thymalfasin (thymosin-alpha1), in combination with peginterferon-alpha2a, has demonstrated efficacy among difficult-to-treat patients with hepatitis C. The addition of ribavirin to Thymalfasin and peginterferon-alpha2a has also exhibited promising results among patients who have genotype 1 hepatitis C, high viral loads and are nonresponders to previous therapy.